Success Metrics

Clinical Success Rate
80.0%

Based on 12 completed trials

Completion Rate
80%(12/15)
Active Trials
7(28%)
Results Posted
58%(7 trials)
Terminated
3(12%)

Phase Distribution

Ph phase_2
15
60%
Ph phase_1
3
12%
Ph phase_3
2
8%
Ph not_applicable
1
4%
Ph phase_4
4
16%

Phase Distribution

3

Early Stage

15

Mid Stage

6

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
3(12.0%)
Phase 2Efficacy & side effects
15(60.0%)
Phase 3Large-scale testing
2(8.0%)
Phase 4Post-market surveillance
4(16.0%)
N/ANon-phased studies
1(4.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

12 of 16 finished

Non-Completion Rate

25.0%

4 ended early

Currently Active

7

trials recruiting

Total Trials

25

all time

Status Distribution
Active(7)
Completed(12)
Terminated(4)
Other(2)

Detailed Status

Completed12
Recruiting7
Terminated3
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
7
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (12.0%)
Phase 215 (60.0%)
Phase 32 (8.0%)
Phase 44 (16.0%)
N/A1 (4.0%)

Trials by Status

unknown28%
withdrawn14%
recruiting728%
terminated312%
completed1248%

Recent Activity

7 active trials
Showing 5 of 25
recruitingphase_2

Monotherapy of an NMDA Enhancer for Schizophrenia

NCT04745143
recruitingphase_2

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

NCT05052853
completedphase_2

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

NCT03928288
completedphase_2

ENAC Blockade and Arterial Stiffness

NCT03837626
recruitingphase_2

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

NCT07122895
View all 25 trials

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT04745143Phase 2

Monotherapy of an NMDA Enhancer for Schizophrenia

Recruiting
NCT05052853Phase 2

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Recruiting
NCT03928288Phase 2

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

Completed
NCT03837626Phase 2

ENAC Blockade and Arterial Stiffness

Completed
NCT07122895Phase 2

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

Recruiting
NCT02989662Phase 1

INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers

Completed
NCT03752294Phase 1

A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

Withdrawn
NCT04637620Phase 2

NMDA Modulation in Major Depressive Disorder

Recruiting
NCT05977023Phase 2

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder

Recruiting
NCT06021197Phase 2

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

Recruiting
NCT05136755Phase 2

NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder

Recruiting
NCT02969382Phase 2

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

Completed
NCT03931070Phase 4

The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU

Completed
NCT03345550Phase 2

OPTIMA-TBI Pilot Study

Terminated
NCT03843112Phase 4

Modulating the Vaginal Microbiome After Implantation Failure

Completed
NCT03425097Phase 2

Fexofenadine Use in Gastroesophageal Reflux Symptoms

Terminated
NCT03592667Phase 4

Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension

Unknown
NCT03414931Phase 2

NMDA Modulation in Major Depressive Disorder in Late- Life

Completed
NCT03006471Phase 4

Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

Completed
NCT03933618Phase 2

Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function

Completed

Drug Details

Intervention Type
DRUG
Total Trials
25